Abstract:Asparaginase is a key component of the therapeutic regimen used to treat patients with acute lymphoblastic leukemia (ALL). Calaspargase pegol (Asparlas) is composed of E. coli L-asparaginase and is PEGylated with approximately 5000 Da polyethylene glycol (PEG). Asparlas depletes asparagine (Asn) by deamination into aspartic acid. Asn synthetase (ASNS) is the key enzyme responsible for de novo Asn synthesis. In the absence of Asn in their direct environment, normal cells having adequate ASNS activity can survive with their own Asn supply while cancer cells lacking ASNS activity undergo apoptosis as they depend on extracellular sources of Asn. The ASNS gene has a typical CpG island in its promoter and its methylation status in tumor cells has been reported to be associated with asparaginase sensitivity clinically in T-ALL and in solid tumors preclinically. In this study we have investigated ASNS promoter hypermethylation as a biomarker for Asparlas activity in solid tumors and explored the feasibility of translating these results into the clinic. Analyses of the TCGA datasets indicated that a relatively high fraction of hepatocellular carcinoma (HCC) and gastric cancers are hypermethylated at the ASNS promoter. Testing Asparlas across a panel of HCC cell lines demonstrated that ASNS promoter-hypermethylated cell lines with lowest ASNS mRNA expression are the most responsive to Asparlas treatment in vitro. In vivo efficacy studies in mice bearing human ASNS promoter-hypermethylated xenograft models of HCC and gastric cancer showed that Asparlas treatment inhibited tumor growth in a dose-dependent manner and resulted in tumor rejections at the highest doses. Data from the HCC model was used to build a PK/PD efficacy model to project efficacious concentrations in patients. A panel of HCC PDX models with different levels of ASNS promoter methylation was evaluated to better understand the relationship between this biomarker and response to Asparlas. Treatment with Asparlas resulted in complete depletion of Asn in plasma and a partial depletion of Asn in the tumor for all models tested and strong anti-tumor activity against a model that had high methylation of the ASNS promoter. This activity was lost in models with lesser degrees of methylation indicating a strict threshold of promoter methylation for efficacy. These data confirm and extend previous findings that hypermethylation of the ASNS promoter has a synthetic lethal relationship with Asn-depleting therapies including Asparlas and highlight the need to carefully define the minimum threshold of hypermethylation to select HCC patients who could potentially benefit from Asparlas treatment. Citation Format: Ethika Tyagi, Magdalena Pohorecka, Valérie Duvivier, Aurelie Studeny, Damien Valour, Natacha Moulharat, Hélène Darville, Nicolas Provost, Pierre Barbier Saint Hilaire, Eef Hoeben, Donald Simons. Asparaginases-Treatment potential for the biomarker selected hepatocellular carcinoma (HCC) population [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2120.

Clinical Efficacy And Toxicity Of Peg-Asparaginase In Patients With Solid Tumor And All: A Meta-Analysis

[A Clinical Observation of Treatment of Peripheral T-cell Lymphoma with L-asparaginase-containing Combination Chemotherapy].

Comparison of efficacy and safety of different asparaginases in adult acute lymphoblastic leukemia based on nano-magnetic beads immunoassay

Safety and adverse event profiling of pegylated L-asparaginase combined chemotherapy in the treatment of lymphoma

[Therapeutic Efficacy of VICP+L-ASP/TKI on Adult Patients with B-ALL].

Clinical Analysis And Prognostic Significance Of L-Asparaginase Containing Multidrug Chemotherapy Regimen In Incipient Peripheral T-Cell Lymphoma

Clinical Analysis of Asparaginase-Associated Pancreatitis in Children.

Abstract 7444: Hepatotoxicity from L-asparaginase is associated with lipid changes in a mouse model

Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase

PEG-asparaginase in BFM-90 Regimen Improves Outcomes in Adults with Newly Diagnosed Lymphoblastic Lymphoma

Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells

Retrospective review of the toxicities and change in dosing patterns for pegaspargase in patients with acute lymphoblastic leukemia/lymphoma and T-cell lymphoma

Therapeutic Efficacy of L-asparaginase in the Treatment of Refractory Midfacial Peripheral T-cell Non-Hodgkin’s Lymphoma

Abstract 2120: Asparaginases-Treatment potential for the biomarker selected hepatocellular carcinoma (HCC) population

[Progress in therapy with L-asparaginase]

Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol

Differential effect of asparagine and glutamine removal on three adenocarcinoma cell lines

[The Efficacy of L-asparaginase in the Treatment of Refractory Midline Peripheral T-cell Lymphoma].

Improving Toxicological, Immune and Inflammatory Responses

Comparison Analysis of First-Line Asparaginase- Versus Non-Asparaginase-based Regimens for Early-Stage Extranodal NK/T-cell Lymphoma.